Vivimed Labs Falls 26.58% in Eight Days: 7 Key Factors Behind the Sharp Decline

29 December 2025: Lower Circuit Triggered Amid Panic Selling

Vivimed Labs opened sharply lower at ₹19.57 on 29 December, hitting its lower circuit limit and closing with a 4.95% loss. The stock remained locked at this price throughout the session, reflecting intense selling pressure and a lack of buying interest. The volume was extremely thin at just 0.00656 lakh shares, indicating near absence of demand. This marked a new 52-week low and a continuation of a four-day losing streak that had already eroded 18.49% of the stock’s value. The broader pharmaceutical sector and Sensex showed resilience, underscoring company-specific challenges.

30 December 2025: Continued Selling Pressure and Lower Circuit Hit

The downward momentum persisted on 30 December as Vivimed Labs again hit its lower circuit at ₹18.60, declining 4.96%. The stock’s volume remained negligible at 0.00014 lakh shares, highlighting illiquidity and sustained panic selling. Over five consecutive sessions, the stock had lost 22.53%, far outpacing sector and market declines. Interestingly, delivery volumes increased by over 105%, suggesting some investors were holding shares despite the price fall, possibly awaiting clarity or a rebound.

31 December 2025: Stock Hits 52-Week Low Amid Weak Financials

On the last trading day of 2025, Vivimed Labs’ stock price plunged to ₹17.67, marking a fresh 52-week low and triggering the lower circuit with a 5.0% loss. This extended the losing streak to six days, with a cumulative decline of 26.41%. The stock’s market capitalisation stood at ₹154 crore, categorising it as a micro-cap with heightened volatility. Despite the broader market and small-cap indices showing gains, Vivimed Labs underperformed significantly. The company’s financials revealed high leverage with a Debt to EBITDA ratio of 12.57 times and a low Return on Equity of 1.75%, alongside a net loss of ₹-281.57 crores for the half-year ended June 2023.

1 January 2026: Seven-Day Losing Streak Continues with Lower Circuit

Vivimed Labs’ stock price declined further to ₹16.79 on 1 January, hitting the lower circuit limit again with a 4.98% loss. This marked the seventh consecutive day of declines, cumulatively eroding approximately 30.07% of the stock’s value. The trading volume remained thin at 0.00949 lakh shares, reflecting limited liquidity and persistent selling pressure. Despite the broader market’s modest gains and the pharmaceutical sector’s slight decline, Vivimed Labs underperformed sharply. The company’s financial challenges, including high leverage and lack of recent disclosures, continued to weigh on investor sentiment.

2 January 2026: Sharpest Daily Decline and Lower Circuit Lock

The stock’s decline culminated on 2 January with a dramatic 9.95% fall to ₹15.08, locking at the lower circuit price for the session. This represented a new 52-week low and extended the losing streak to eight consecutive sessions, with a cumulative loss of 37.03%. The total traded volume was just 0.00972 lakh shares, underscoring the stock’s illiquidity. While delivery volumes had increased the previous day, indicating some investor interest, panic selling dominated on 2 January. The stock’s Mojo Score remained low at 24.0 with a Strong Sell grade, reflecting deteriorated fundamentals and negative market sentiment.

Daily Price Performance vs Sensex

Key Takeaways

Severe Downtrend: Vivimed Labs experienced an eight-day losing streak, with a cumulative decline of 26.58%, sharply underperforming the Sensex’s 1.35% gain over the same period.

Repeated Lower Circuit Hits: The stock hit its lower circuit limit on five separate trading days, reflecting intense panic selling and lack of buyer interest.

Liquidity Constraints: Extremely thin trading volumes and low turnover exacerbated price volatility and limited the stock’s ability to absorb selling pressure.

Weak Financial Fundamentals: High leverage with a Debt to EBITDA ratio of 12.57 times, low Return on Equity of 1.75%, and significant net losses have weighed heavily on investor sentiment.

Strong Sell Rating: The Mojo Score of 24.0 and a Strong Sell grade assigned on 22 December 2025 reflect deteriorating fundamentals and a negative outlook.

Investor Behaviour: Delivery volumes showed mixed signals, with some increase indicating holding interest, but overall panic selling dominated the week.

Sector and Market Divergence: While the broader pharmaceutical sector and Sensex showed resilience, Vivimed Labs’ stock underperformed significantly, highlighting company-specific challenges.

Conclusion

Vivimed Labs’ stock performance over the week ending 2 January 2026 paints a picture of a micro-cap pharmaceutical company grappling with severe selling pressure, weak financials, and limited liquidity. The repeated lower circuit hits and sharp price declines underscore the heightened risk and volatility associated with the stock. Despite some technical support from longer-term moving averages, the prevailing market sentiment remains bearish, reinforced by the strong sell rating and deteriorating fundamentals. Investors should exercise caution and closely monitor any forthcoming corporate developments or sectoral shifts before considering exposure to this volatile stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →